Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service.
BörsenkürzelVVOS
Name des UnternehmensVivos Therapeutics Inc
IPO-datumDec 11, 2020
CEOMr. R. Kirk Huntsman
Anzahl der mitarbeiter109
WertpapierartOrdinary Share
GeschäftsjahresendeDec 11
Addresse7921 Southpark Plaza,
StadtLITTLETON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl80120
Telefon18669084867
Websitehttps://vivos.com/
BörsenkürzelVVOS
IPO-datumDec 11, 2020
CEOMr. R. Kirk Huntsman
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten